The company has financially committed more than $3.8 billion since the COVID-19 pandemic into keeping the medication and vaccine production process in France.
The CDMO’s Bedford, NH facility will welcome a new isolator filling line—along with twin lyophilizers—as part of a multi-year, $100 million capital investment project.